AgomAb Therapeutics NV was originally incorporated under the laws of Belgium on April 13, 2017 and is a Belgian private limited liability company. The Company is a clinical-stage biopharmaceutical entity developing innovative disease-improving therapies for immunological and inflammatory diseases, with a particular focus on chronic fibrotic diseases with significant unmet medical needs. Its product candidates are designed to target established pathways and use proven models to enhance efficacy while minimizing systemic toxicity, thereby addressing the limitations of previous treatments. Its mission is to create therapies that not only address fibrosis, but also restore organ function, allowing patients to live fuller and healthier lives.